Results 71 to 80 of about 739,667 (342)

The role of circular RNAs in regulating cytokine signaling in cancer

open access: yesFEBS Open Bio, EarlyView.
Cytokines present in the tumor microenvironment fuel cancer development. Aberrant expression of circRNAs contributes to cancer progression. Cytokines are involved in regulating circRNA biogenesis. Furthermore, aberrantly expressed circRNAs regulate the expression of ligands, receptors, and downstream effectors involved in cytokine signaling to promote ...
Vandana Joshi   +4 more
wiley   +1 more source

Real-world impact of transitioning from one lipoprotein(a) assay to another in a clinical setting

open access: yesAmerican Journal of Preventive Cardiology
Background and aims: Different lipoprotein(a) [Lp(a)] assays may affect risk stratification of individuals and thus clinical decision-making. We aimed to investigate how transitioning between Lp(a) assays at a large central laboratory affected the ...
Janeni Jeevanathan   +10 more
doaj   +1 more source

Hepatitis C virus relies on lipoproteins for its life cycle [PDF]

open access: yes, 2016
Hepatitis C virus (HCV) infects over 150 million people worldwide. In most cases, HCV infection becomes chronic causing liver disease ranging from fibrosis to cirrhosis and hepatocellular carcinoma.
Alonzi, Tonino   +5 more
core   +1 more source

Liver‐specific lncRNAs associated with liver cancers

open access: yesFEBS Open Bio, EarlyView.
Long non‐coding RNAs (lncRNAs) are regulatory molecules with various functions. They are more tissue‐specific than proteins and can be used as potential biomarkers, particularly in cancer diagnostics and prognosis. In this review, we have systematically compiled all lncRNAs with exclusive expression in the human liver, verified their liver specificity ...
Olga Y. Burenina   +3 more
wiley   +1 more source

Lipoprotein(a) throughout life in women

open access: yesAmerican Journal of Preventive Cardiology
Lipoprotein (a) [Lp(a)] is a lipoprotein with multiple deleterious characteristics and is a recognized cardiovascular (CV) risk factor. The pro-atherogenic, pro-thrombotic, and pro-inflammatory features of Lp(a) are associated not only with ...
Pablo Corral   +6 more
doaj   +1 more source

Association of apolipoproteins and lipoprotein(a) with metabolic syndrome: a systematic review and meta-analysis

open access: yesLipids in Health and Disease, 2023
Background & aims Apolipoproteins and lipoprotein(a) are associated with various cardiometabolic diseases, including insulin resistance, diabetes mellitus, hypertension, dyslipidemia, among others.
Juan R. Ulloque-Badaracco   +8 more
doaj   +1 more source

Report on the 2nd MObility for Vesicle research in Europe (MOVE) symposium—2024

open access: yesFEBS Open Bio, EarlyView.
The 2nd MObility for Vesicle research in Europe (MOVE) Symposium in Belgrade brought over 280 attendees from 28 countries to advance extracellular vesicle (EV) research. Featuring keynotes, presentations, and industry sessions, it covered EV biogenesis, biomarkers, therapies, and manufacturing.
Dorival Mendes Rodrigues‐Junior   +5 more
wiley   +1 more source

Lipoprotein(a) and the atherosclerotic burden – Should we wait for clinical trial evidence before taking action?

open access: yesAtherosclerosis Plus
The fact that lipoprotein(a) levels should be regarded as a causal residual risk factor in the atherosclerotic cardiovascular diseases (ASCVD) is now a no-brainer.
Isabella Fichtner   +5 more
doaj   +1 more source

Lipoproteins of Mycobacterium tuberculosis : an abundant and functionally diverse class of cell envelope components [PDF]

open access: yes, 2004
Mycobacterium tuberculosis remains the predominant bacterial scourge of mankind. Understanding of its biology and pathogenicity has been greatly advanced by the determination of whole genome sequences for this organism.
Harrington, Dean, Sutcliffe, Iain
core   +1 more source

Durability of Response to B‐Cell Maturation Antigen‐Directed mRNA Cell Therapy in Myasthenia Gravis

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective We report the 12‐month follow‐up outcomes from a Phase 2 clinical trial (NCT04146051) evaluating Descartes‐08, a BCMA‐directed RNA chimeric antigen receptor T‐cell (rCAR‐T) therapy for refractory generalized myasthenia gravis (MG).
Nizar Chahin   +10 more
wiley   +1 more source

Home - About - Disclaimer - Privacy